Table 1. Comparison of WHO classification of anti-tuberculosis drugs between 2014 and 2016 guidelines15,21.
| WHO 2014 | WHO 2016 | |||
|---|---|---|---|---|
| Group | Drugs | Group | Drugs | |
| Group 1 | Isoniazid Rifampicin Ethambutol Pyrazinamide Rifabutin, rifapentine |
- | - | |
| Group 2 | Streptomycin Kanamycin Amikacin Capreomycin |
Group A* | Levofloxacin Moxifloxacin Gatifloxacin |
|
| Group 3 | Levofloxacin Moxifloxacin Gatifloxacin |
Group B | Amikacin Capreomycin Kanamycin (streptomycin)† |
|
| Group 4 | Ethionamide Prothionamide Cycloserine Terizidonee p-Aminosalicylic acid |
Group C* | Ethionamide/prothionamide Cycloserine/terizidone Linezolid Clofazimine |
|
| Group 5 | Bedaquiline Delamanid Linezolid Clofazimine Amoxicillin/clavulanate Imipenem/cilastatin Meropenemf High-dose isoniazid Thioacetazone Clarithromycin |
Group D | D1 | Pyrazinamide |
| Ethambutol | ||||
| High-dose isoniazid | ||||
| D2 | Bedaquiline | |||
| Delamanid | ||||
| D3 | p-Aminosalicylic acid | |||
| Imipenem-cilastatin‡ | ||||
| Meropenem‡ | ||||
| Amoxicillin-clavulonate‡ (thioacetazone) | ||||
*Medicines in groups A and C are shown by decreasing order of usual preference for use. †Streptomycin may substitute other injectable agents when the other three cannot be used. ‡Carbapenems and clavulanate are meant to be used together; clavulanate is only available in formulations combined with amoxicillin.